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Abstract
Takotsubo syndrome was featured in various sessions and posters at the recent Heart Failure Congress and World Congress on
Acute Heart Failure 2019 held in Athens. The importance and increasing recognition of this acute heart failure syndrome is
reﬂected by the growing activity at Heart Failure Association congresses over the last 8 years. Two dedicated sessions to
Takotsubo syndrome with comprehensive lectures from experts in the ﬁeld and several posters highlighted new scientiﬁc
progress, important aspects of epidemiology, pathophysiology, risk stratiﬁcation, and management of the syndrome and
discussed gaps in knowledge of this intriguing entity. This paper will summarize the topics discussed in these sessions including
the most recent data from large registries, clinical, and pre-clinical studies presented at the meeting.
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Introduction
Heart Failure 2019 Congress, the largest congress worldwide
about heart failure (HF) with more than 5400 attendees this
year in Athens, covered almost every modern topic in HF,
justifying the title: Heart failure from Alpha to Omega.
Takotsubo syndrome (TTS), a relatively recently described
clinical entity, included in the differential diagnosis of the
causes of acute HF, is an important medical condition
discussed at the congress. The growing understanding of its
pathophysiology, the numerous challenges in its treatment
but also its research interest, made TTS sessions (Table S1)
popular for attendees. A range of new information and
expert opinions were presented at the meeting, which we
summarize in this article.
Epidemiology
Data from the nationwide Swedish Coronary Angiography
and Angioplasty registry conﬁrm the preponderance of
women in TTS population with a percentage of 73%.1 Men
with TTS have disproportionally worse prognosis than
women. From the same registry, it is obvious that TTS differs
between different health care regions within Sweden with
the highest reported incidence in the Western health care
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region, whereas mortality is higher in the Southern region.2
The temporal pattern of TTS is similar to that of acute
coronary syndromes (ACS) with peak during winter, while
the least cases of TTS appear in spring and of ACS in
summer.3
Deﬁnition
The deﬁnition of TTS according to the two most recent posi-
tion papers4,5 involves several diagnostic criteria (Figure 1),
most of which are common and include transient regional
wall motion abnormalities (RWMAs) of the left ventricle
(LV) and/or the right ventricle (RV) after a stressful trigger
(emotional, physical, or combined, neurologic disorders, or
pheochromocytoma), RWMAs extend beyond the distribu-
tion of a single coronary artery, new and reversible electro-
cardiographic (ECG) abnormalities, elevated serum
natriuretic peptides, and relatively small troponin elevation.
The InterTAK diagnostic score6 includes seven criteria
(female sex, physical trigger, emotional trigger, absence of
ST depression, psychiatric disorder, neurologic disorders,
and QTc prolongation). A score > 70 increases signiﬁcantly
the possibility of TTS, but as Dr Di Vece underlined, the pre-
dicted probability of TTS depends on the prevalence of the
disease in the population applied and in clinical practice,
coronary imaging is essential to exclude other diagnoses. LV
end-diastolic pressure may be normal, near normal, or ele-
vated in TTS whereas it is usually elevated in ACS.7
Although transient myocardial dysfunction is considered a
prerequisite in the deﬁnition of TTS, there is evidence that
myocardial recovery is not full 4 months after the acute
phase of TTS, demonstrated by deformation indices8 and also
cardiac energetic status and intense myocardial oedema.9
Professor Dana Dawson presented the results of HEROIC
study10 and even a year after the acute episode, there is per-
sistent subclinical cardiac dysfunction. Unremitting symptoms
compatible with HF, cardiac limitation on exercise testing,
signiﬁcantly impaired deformation mechanics, and cardiac
energetic status reafﬁrm the long-term structural, functional,
and metabolic changes in TTS patients.
Professor Omerovic and Dr Di Vece presented two cases
that proved that TTS and coronary artery disease can co-exist.
Approximately 15% of patients with TTS have concomitant
coronary artery disease with signiﬁcant impact upon out-
comes. Another issue is that in one third of patients, there
Figure 1 Similarities and differences between Heart Failure Association and International Takotsubo Diagnostic Criteria.
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is no trigger—physical or emotional according to Interna-
tional Takotsubo Registry.11
RWMAs deﬁne the type of TTS with apical TTS (typical
type) being the most common (~80%). Atypical types of TTS
(midventricular, reversed, and focal) have distinct patterns
in echocardiographic images or in ventriculography. Diagnosis
of focal TTS can be challenging. Apical TTS presents with the
lowest LV ejection fraction (LVEF) in the acute phase, while
after 60 days, there is no signiﬁcant difference in LV systolic
function between the different types. There is some contro-
versy in the literature concerning long-term prognosis. Ghadri
et al.12 reported that all TTS types have similar prognosis af-
ter 1-year follow-up from the large InterTak registry, while
another study suggests that apical TTS is associated with
higher mortality within the ﬁrst 6 months but after
complete recovery of LV systolic function, prognosis is the
same.13 Dr Di Vece reported that patients with TTS enrolled
in an Italian registry with LVEF ≤ 35% at presentation are at
higher risk not only in the acute phase but also at long-term
follow-up.14
Diagnosis
ECG changes comprising of ST segment elevation, T wave in-
version, QT prolongation and less frequently left bundle
branch block, atrial ﬁbrillation, and ST depression are typical
of TTS, but a normal ECG does not exclude the diagnosis.11
Dr Yoshihiru Akashi reviewed the ECG changes observed in
TTS patients. Dr Akashi explained that ST depression in aVR
and absence of ST elevation in V1 suggest TTS with sensitivity
and speciﬁcity > 90%.15 Troponin elevation is usually
disproportionally low to the extent of myocardium involved,
while NT-proBNP levels are higher at admission compared
with ACS.16 Echocardiography17 and cardiac magnetic reso-
nance18 are the main imaging modalities used in the diagno-
sis of TTS, and its complications provide signiﬁcant prognostic
information. A comprehensive diagnostic algorithm in the
emergency department can be used to differentiate TTS vs.
ACS or myocarditis.19
Pathophysiological insights
Several clinical and preclinical studies support the central role
of sympathetic nervous system and catecholamines in TTS by
inducing myocardial stunning. Dr Ciccarelli described how cat-
echolamine levels are markedly higher in patients with TTS
compared with matched controls and patients with left
anterior descending artery occlusion and ST elevation myo-
cardial infarction.20 Nonetheless, the central role of catechol-
amines in TTS is demonstrated by intravenous study
administration of catecholamines, and beta-receptor agonists
led immediately to the development of TTS.21 Another
interesting observation from preclinical studies is that norepi-
nephrine predominately is released in basal myocardial re-
gions where sympathetic innervation is highest, while
epinephrine has the greatest effect in apical regions where
β-adrenoceptor density is highest. Norepinephrine is the
main catecholamine released from sympathetic nerve end-
ings, whereas epinephrine among circulating catecholamines.
These heterogeneities may explain the RWMAs in TTS be-
cause of changes in adrenoceptor density and/or sensitivity,
as well as alterations in downstream signalling pathways.22
G protein-coupled receptor kinases (GRKs) are tightly re-
lated to the adrenergic system through mechanisms of de-
sensitization and down-regulation, and they also seem to
play a role in the pathophysiology of TTS. Speciﬁcally, L41Q
polymorphism of GRK5, one of the two isoforms predominant
in the heart, makes patients susceptible to TTS.23,24 An inter-
esting study showed that GRK2 and β-arrestin 2 expression in
the myocardium was higher in TTS than in dilated cardiomy-
opathy or controls in the acute phase, supporting the concept
that β-adrenergic receptors on the cell membrane are modi-
ﬁed by GRK2 and β-arrestin 2, conﬁrming their role in the
development of LV dysfunction in TTS.25
Risk assessment—prognosis
Professor Elmir Omerovic highlighted that TTS is not a benign
condition as it is associated with signiﬁcant complications
such as acute HF, mitral regurgitation (MR), cardiogenic
shock, and malignant ventricular arrhythmias that can impact
on prognosis.4 RV involvement is present in 15% of TTS
patients with increased in-hospital rate of major adverse car-
diovascular events.26 Risk stratiﬁcation of patients with TTS
should take into account numerous variables including age,
systolic blood pressure, presence of pulmonary oedema,
MR, apical thrombus, new ventricular septal defect or LV rup-
ture and LVEF and LV outﬂow track obstruction (LVOTO).4 TTS
has substantial morbidity and mortality, with rate of major
adverse cardiovascular events 9.9% per patient-year and rate
of death 5.6% per patient-year in the International Takotsubo
Registry with long-term follow-up.11
Arrhythmias
In the risk stratiﬁcation of patients with TTS, certain
arrhythmias/ECG characteristics should be taken in account;
ventricular tachycardia, ventricular ﬁbrillation, QTc >500
ms, abnormal Q wave, and prolonged ST elevation are consid-
ered factors of high-risk patients.4 QTc prolongation is also in-
cluded in the diagnostic criteria of InterTAK Diagnostic Score,
adding six points to the total score.5 QRS duration on admis-
sion has signiﬁcant prognostic impact, with prolonged dura-
tion associated with higher incidence of all-cause death,
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cardiac death, ventricular arrhythmias, atrioventricular block,
use of catecholamines, and various circulatory support
devices.27 Recently Jesel et al.28 showed that 105 ms is the
optimal cut-off value of QRS duration for predicting the risk
of life-threatening arrhythmias. The presence of J wave is
another factor that is associated with increased risk of cardiac
death and cardiac arrhythmia in TTS patients.29 Negative
prognostic risk factors are also high heart rate on admission
and atrial arrhythmias, including atrial ﬁbrillation and atrial
ﬂutter.
Dr Olivier Morel delivered his lecture focusing on the ar-
rhythmias seen in TTS patients and the underlying cardiac
electrophysiology. The prevalence of atrial arrhythmias in
TTS is 18–25%, and they are associated with higher in-
hospital mortality, 30-day mortality, all-cause mortality, and
cardiovascular mortality.30 Supraventricular arrhythmias
could be related to atrial stretch/impairment, but inﬂamma-
tion has possibly a role too.31
The prevalence of ventricular arrhythmias is 2–10%, and
the prevalence of all life-threatening arrhythmias including
torsades de pointes, ventricular ﬁbrillation, complete heart
block, sinoatrial block, asystole, and pulseless electrical activ-
ity is 13.5%.28 Most ventricular arrhythmias occur within the
ﬁrst 24 h and are associated with signiﬁcantly worse short-
term and long-term prognosis. Catecholamine surge,
inﬂammation/oedema, ischaemia, and lack of estrogens are
the main pathophysiological mechanisms responsible for
electrical instability in TTS. Therapeutically, implantable
cardioverter deﬁbrillator implantation is not indicated as the
arrhythmic risk is generally transient, while there is an indica-
tion for pacemaker implantation, if atrioventricular conduc-
tion abnormalities persist.
Management
Dr Alexander Lyon reviewed the clinical management of TTS
and emphasized that currently there have been no trials to
guide management decisions and therefore current pathways
of care are based on expert opinion and depend upon the
type of TTS (primary or secondary) and the level of risk. In
case of secondary TTS where there is also another medical
or surgical emergency, it is important to optimize treatment
of the underlying condition to lower sympathetic drive.
Lower risk patients with LVEF > 45% do not need any
treatment, while if LVEF is 35–45%, an angiotensin-converting
enzyme inhibitor and a beta-blocker are recommended in the
recent Heart Failure Association (HFA) position statement.4
Dr Lyon explained that in his opinion, carvedilol is the pre-
ferred choice if there is no LVOTO, while β1 adrenergic recep-
tor speciﬁc blockers are preferred in cases of severe LVOTO.4
Higher risk patients with TTS should be treated in coronary
care unit or high dependency units setting for at least 72 h.
Additionally, if there is an apical thrombus, low-molecular-
weight heparin should be administered and then oral
anticoagulation for at least 3 months. The role of direct oral
anticoagulants vs. warfarin needs to be deﬁned.
In the advanced cases of cardiogenic shock, extra-
corporeal membrane oxygenation or left ventricular assist
device should be considered, but if not available, then
levosimendan can be used, starting at low dose and up-
titrating slowly. Avoidance of nebulized β2 agonists, iatro-
genic catecholamines, and QTc prolonging drugs and stopping
selective serotonin reuptake inhibitors and serotonin and
norepinephrine reuptake inhibitors are also important.
Dr Lyon argued that long-term follow-up and care are
needed in cases with ongoing cardiac symptoms and recur-
rent TTS. Chronic chest pain, exertional dyspnoea, and
arrhythmias are the main chronic symptoms. In his experi-
ence, carvedilol, ranolazine, and diltiazem may be helpful,
while non-steroidal anti-inﬂammatory drugs, selective seroto-
nin reuptake inhibitors, and serotonin and norepinephrine
reuptake inhibitors should be avoided. Electrophysiology
review and ablation of refractory atrial and ventricular
arrhythmias are the suggested treatments if symptomatic
and refractory to medical therapy in patients with TTS.
Psychological support and stress management counselling
are considered to play key roles in the chronic treatment of
TTS patients, and support groups on Facebook or patient sup-
port websites (www.takotsubo.net) provide patient-centred
support. Special reference must be made to spontaneous
and recurrent TTS cases where it is recommended to screen
these patients for pheochromocytoma.
Case reports
Interesting cases were presented as posters or moderated
posters illuminating the co-existence of TTS with other clinical
entities, such as Guillain–Barre syndrome,32 pathology of the
coronary arteries (spontaneous dissection),33 or as a pheno-
copy of apical hypertrophic cardiomyopathy (HCM).34 Typical
TTS in the acute phase can mimic apical HCM because of ECG
changes and apical RWMAs, making the diagnosis of HCM or
TTS possible only after recovery. Another instructive case pre-
sented by Zaw et al.35 demonstrated a possible association of
HCM with TTS, suggesting that the responsible pathophysio-
logic mechanism could be basal septal hypertrophy and cate-
cholamine driven LVOTO. Treatment of TTS in patients with
severe MR and LVOTO, if complicated with acute pulmonary
oedema, should be cautious with regards to diuretics and
nitrates, as they can increase LVOT gradient.36
A unique case of cardiotoxicity was presented by Belarte
Tornero et al.37 with TTS evolving to cardiogenic shock in a
patient with BRAF-mutated metastatic lung cancer under
treatment with trametinib.37 Suppression of MEK and
ERK1/2 activation in the heart is the suggested underlying
4 K. Keramida et al.
ESC Heart Failure (2020)
DOI: 10.1002/ehf2.12603
mechanism, and periodic cardiac screening may be necessary
in patients treated with trametinib.
A case of successful cardiac transplantation from a donor
with TTS was presented by Professor Omerovic E. The donor
was a 59-year-old woman with subarachnoid haemorrhage,
mid-ventricular akinesia, and LVEF ~35% who met the ESC
Takotsubo working group criteria for secondary TTS. The re-
cipient was a middle-aged man with biventricular congestive
HF because of dilated cardiomyopathy. Cardiac function of
the transplanted heart recovered within 2 weeks. This case
belongs to a cohort of donors with TTS (n = 42) from the
same group. New onset of left ventricular dysfunction in or-
gan donors is frequent and considered as a contraindication
for utilization of the heart. However, such dysfunction is of-
ten caused by TTS and is therefore transient. The Gothenburg
group has recently shown (38) that transplantation of hearts
from donors with TTS has similar long-term survival as from
donors with normal heart function. If proven true by random-
ized clinical trial, this strategy could lead to increase organ
availability by ~25% and therefore improved survival and
quality of life in patients with terminal HF.
Gaps in knowledge
There are several issues concerning pathophysiology, treat-
ment, and prognosis that require further research to improve
our understanding of the syndrome and patients’ outcome.
What is the cause of akinesia with the characteristic pattern
in LV and/or RV? Why do some individuals develop TTS while
others with the same triggers do not? Is there a genetic or
environmental substrate? Why there is such a preponderance
of postmenopausal women? What is the endocrine–cardiac
speciﬁc interaction in women that makes them susceptible
to this syndrome? How do patients with TTS and extensive
LV dysfunction survive while patients with myocardial infarc-
tions of comparable extent of affected myocardium do not?
What are the responsible mechanisms for LV recovery? What
are the predisposing risk factors for life-threatening arrhyth-
mias? Is inﬂammation a causative factor or an effect of
TTS? What is the best treatment strategy in this population
in the acute phase but also long term? What should be the
duration of medical treatment of patients with TTS in case
of complete and/or incomplete LV recovery?
Conclusions
Interesting research and expert opinion regarding the man-
agement of TTS was presented in HFA 2019 Congress. Many
more questions were also discussed, highlighting the need
for additional research and clinical trials. The next HFA
Congress will be hosted in Barcelona in May 2020 and will re-
view the clinical management of TTS, new insights into path-
ophysiology, and hopefully provide the answers to many of
the questions raised at the recent 2019 HFA Summer
Congress.
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